Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Brazilian (BOVESPA) Healthcare Sector Analysis

UpdatedDec 31, 2025
DataAggregated Company Financials
Companies16
  • 7D-0.8%
  • 3M-6.6%
  • 1Y30.2%
  • YTD32.0%

Last week, the Healthcare industry hasn't moved much but Hapvida Participações e Investimentos is up 4.1% in that time. As for the the longer term, the industry is up 30% over the past 12 months. As for the next few years, earnings are expected to grow by 29% per annum.

Sector Valuation and Performance

Has the Brazilian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 31 Dec 2025R$144.4bR$152.1bR$1.8b12.1x78.2x0.9x
Fri, 28 Nov 2025R$154.7bR$152.1bR$1.9b12.6x83.2x1x
Sun, 26 Oct 2025R$151.4bR$149.9bR$2.5b11.5x60.7x1x
Tue, 23 Sep 2025R$153.9bR$149.9bR$2.5b11.9x61.7x1x
Thu, 21 Aug 2025R$143.0bR$144.3bR$2.5b12.3x57.2x1x
Sat, 19 Jul 2025R$131.7bR$149.5bR$2.0b11x64.6x0.9x
Mon, 16 Jun 2025R$140.9bR$149.5bR$2.0b11.1x69.1x0.9x
Wed, 14 May 2025R$138.4bR$149.1bR$2.2b10.8x63.9x0.9x
Fri, 11 Apr 2025R$119.0bR$150.7bR$3.6b10.5x33.3x0.8x
Sun, 09 Mar 2025R$118.2bR$146.8bR$4.7b11.1x25.2x0.8x
Tue, 04 Feb 2025R$117.6bR$146.7bR$4.7b11.5x25.2x0.8x
Thu, 02 Jan 2025R$110.2bR$146.7bR$4.7b11.3x23.6x0.8x
Sat, 30 Nov 2024R$120.2bR$148.2bR$5.3b11.9x22.9x0.8x
Mon, 28 Oct 2024R$138.5bR$144.9bR$4.4b11.2x31.5x1x
Wed, 25 Sep 2024R$151.8bR$144.9bR$4.4b11.3x34.5x1x
Fri, 23 Aug 2024R$156.7bR$144.9bR$4.4b11.8x35.6x1.1x
Sun, 21 Jul 2024R$142.2bR$143.3bR$4.2b11.6x34.1x1x
Tue, 18 Jun 2024R$132.4bR$142.9bR$4.2b11.2x31.6x0.9x
Thu, 16 May 2024R$152.6bR$142.8bR$4.2b12.2x36.1x1.1x
Sat, 13 Apr 2024R$137.1bR$140.0bR$3.2b12.1x43.2x1x
Mon, 11 Mar 2024R$145.0bR$133.5bR$2.8b14.6x52.5x1.1x
Wed, 07 Feb 2024R$151.0bR$132.9bR$2.7b18.3x55.7x1.1x
Fri, 05 Jan 2024R$162.8bR$135.0bR$2.9b19.8x56.5x1.2x
Sun, 03 Dec 2023R$162.7bR$135.0bR$2.9b20.2x56.4x1.2x
Tue, 31 Oct 2023R$137.5bR$126.2bR$2.8b17.7x49.5x1.1x
Thu, 28 Sep 2023R$158.1bR$126.1bR$2.7b19.1x57.5x1.3x
Sat, 26 Aug 2023R$177.8bR$126.1bR$2.7b20.3x64.7x1.4x
Mon, 24 Jul 2023R$189.6bR$116.7bR$2.8b16.7x67.3x1.6x
Wed, 21 Jun 2023R$181.5bR$116.7bR$2.8b16.6x64.1x1.6x
Fri, 19 May 2023R$155.9bR$110.6bR$2.8b14.9x55.1x1.4x
Sun, 16 Apr 2023R$133.2bR$106.3bR$3.3b14.8x40.1x1.3x
Tue, 14 Mar 2023R$138.6bR$103.8bR$3.8b14.8x36.8x1.3x
Thu, 09 Feb 2023R$170.0bR$98.3bR$4.2b15.6x40.8x1.7x
Sat, 07 Jan 2023R$166.4bR$98.3bR$4.2b15.1x39.9x1.7x
Price to Earnings Ratio

39.9x


Total Market Cap: R$166.4bTotal Earnings: R$4.2bTotal Revenue: R$98.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Brazilian Healthcare Sector Price to Earnings3Y Average 48.8x20242025
Current Industry PE
  • Investors are optimistic on the Brazilian Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 78.2x which is higher than its 3-year average PE of 48.8x.
  • The 3-year average PS ratio of 1.1x is higher than the industry's current PS ratio of 0.95x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 24% per year over the last three years.
  • Meanwhile revenues for these companies have grown 16% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Brazilian Healthcare sector?

BR Market0.35%
Healthcare-0.85%
Biotech6.83%
Medical Equipment1.62%
Pharma1.41%
Healthcare Services-1.33%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 108x.
    • Analysts are expecting annual earnings growth of 29.4%, which is higher than its past year's earnings growth of 7.1% per year.
  • Investors are most pessimistic about the Medical Equipment industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average of 0.79x.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 29% over the next 5 years.
  • This is better than its past earnings growth rate of 7.1% per year.
  • In contrast, the Biotech industry is expected to see its earnings grow by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HAPV3 Hapvida Participações e InvestimentosR$14.734.1%
+R$287.2m		-56.0%PS0.2x
HYPE3 HyperaR$23.561.6%
+R$240.5m		30.2%PE18.1x
DASA3 Diagnósticos da AméricaR$4.544.1%
+R$225.0m		138.9%PS0.5x
BLAU3 Blau FarmacêuticaR$14.057.9%
+R$183.0m		6.8%PE7.7x
ONCO3 Oncoclínicas do Brasil Serviços MédicosR$2.713.4%
+R$100.3m		15.8%PS0.5x

Latest News

HYPE3
R$23.56
Hypera
7D
1.6%
1Y
30.2%

Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt

Dec 28
Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
RDOR3
R$40.61
Rede D'Or São Luiz
7D
-2.5%
1Y
59.8%

RDOR3: Future Market Pricing Will Reflect Strengthening Profit Margins Ahead

Analysts have slightly reduced their price target for Rede D'Or São Luiz to R$49.19 from R$49.48, reflecting modest tweaks to long term assumptions on discount rates, revenue growth, profit margins and future valuation multiples. Valuation Changes Fair Value Estimate: decreased slightly from R$49.48 to R$49.19, reflecting a marginally lower long term intrinsic valuation.
HAPV3
R$14.73
Hapvida Participações e Investimentos
7D
4.1%
1Y
-56.0%

HAPV3: Higher Risk Premium Will Still Support Attractive Upside Potential

Analysts have reduced their price target for Hapvida Participações e Investimentos from R$85.44 to R$50.00, citing expectations for slower revenue growth, thinner profit margins, a higher perceived risk profile, and a lower justified future price to earnings multiple. Valuation Changes The fair value estimate was reduced significantly from R$85.44 to R$50.00, reflecting a materially lower assessment of long term intrinsic value.
OFSA3
R$23.00
Ouro Fino Saúde Animal Participações
7D
-1.3%
1Y
18.9%
ODPV3
R$11.20
Odontoprev
7D
0.6%
1Y
3.1%

Some Confidence Is Lacking In Odontoprev S.A.'s (BVMF:ODPV3) P/E

Dec 19
Some Confidence Is Lacking In Odontoprev S.A.'s (BVMF:ODPV3) P/E
ONCO3
R$2.71
Oncoclínicas do Brasil Serviços Médicos
7D
3.4%
1Y
15.8%

ONCO3: Lower Margins And Reduced Earnings Multiple Will Pressure Future Returns

Analysts have modestly reduced their price target on Oncoclínicas do Brasil Serviços Médicos by approximately 25 percent, reflecting a slightly lower fair value and profit margin outlook that is only partially offset by improved revenue growth expectations and a modestly reduced discount rate. What's in the News A special and extraordinary shareholders meeting is scheduled for January 7, 2026, to be held at Rua Augusta 1.562, 12th floor, Consolação, São Paulo, Brazil (company event filing) Valuation Changes The Fair Value estimate has fallen significantly, moving from 2.0x to 1.5x.
MATD3
R$5.26
Hospital Mater Dei
7D
-4.0%
1Y
44.5%
BLAU3
R$14.05
Blau Farmacêutica
7D
7.9%
1Y
6.8%

BLAU3: Future Margins And U.S. Expansion Are Expected To Support Returns

Analysts have raised their price target on Blau Farmacêutica from R$13.00 to R$14.50, citing slightly higher projected revenue growth, modestly improved profit margins, and a richer future P E multiple, despite a marginal uptick in the discount rate. What's in the News The board approved payment of R$ 20 million in Interest on Equity for the fourth quarter of 2025, reinforcing shareholder remuneration plans (Key Developments).
DASA3
R$4.54
Diagnósticos da América
7D
4.1%
1Y
138.9%

There's Reason For Concern Over Diagnósticos da América S.A.'s (BVMF:DASA3) Massive 68% Price Jump

Dec 13
There's Reason For Concern Over Diagnósticos da América S.A.'s (BVMF:DASA3) Massive 68% Price Jump
AALR3
R$5.05
Alliança Saúde e Participações
7D
5.2%
1Y
-40.9%
BIOM3
R$7.22
Biomm
7D
4.2%
1Y
-32.3%
VVEO3
R$1.42
CM Hospitalar S/A
7D
-0.7%
1Y
-30.7%